Grant: CIHR Fellowship
Direct Payment
$100,000.00
Reprogramming tumour immunogenicity with STING-Nanoparticles
FY 2017-18
Summary
One hallmark of cancers is that it is capable of escaping detection by the immune system. This ability allows cancer to grow uncontrollably without triggering an immune response that would result in its destruction. Immunotherapy seeks to harness the immune system to destroy cancer by activating tumour-specific T cells. This will allow for the training of the immune system to "remember" how to detect and kill cancer cells if they return. The goal of this research is to develop an effective approach for increasing anti-tumour immune system response within cancer. Studies have shown that the stimulator of interferon genes (STING) pathway within the body plays an important role in the immune system's natural ability to recognize and destroy tumour cells. This pathway can be activated through the delivery of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) to tumour cells. However, two challenges are associated with the administration of cGAMP to patients. The physio-chemical properties of the molecule result in (i) rapid elimination from the body and (ii) toxicity. Thus, a novel STING-activating nanoparticle will be engineered to allow for improved delivery and decreased toxicity of cGAMP. The nanoparticles, tiny bubbles composed of biocompatible polymers, are called polymerosomes and can be used to encapsulate cGAMP reducing its exposure to the body. This will create a safer formulation of cGAMP, which can be tested further in animal tumour models. It is expected that this formulation will activate the STING pathway, which will result in an immune response that will destroy tumour cells and create lasting T cell memory in the case of relapse.
Department
Program
CIHR Fellowship
Recipient
Location
Tennessee, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
376870
Name
Wehbe Mohamed
Region
Tennessee
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Reprogramming tumour immunogenicity with STING-Nanoparticles
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer Therapy; Cgamp; Drug Delivery; Immunotherapy; Nanoparticle; Nanotechnology; Polymerosomes; Sting
Abstract
One hallmark of cancers is that it is capable of escaping detection by the immune system. This ability allows cancer to grow uncontrollably without triggering an immune response that would result in its destruction. Immunotherapy seeks to harness the immune system to destroy cancer by activating tumour-specific T cells. This will allow for the training of the immune system to "remember" how to detect and kill cancer cells if they return. The goal of this research is to develop an effective approach for increasing anti-tumour immune system response within cancer. Studies have shown that the stimulator of interferon genes (STING) pathway within the body plays an important role in the immune system's natural ability to recognize and destroy tumour cells. This pathway can be activated through the delivery of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) to tumour cells. However, two challenges are associated with the administration of cGAMP to patients. The physio-chemical properties of the molecule result in (i) rapid elimination from the body and (ii) toxicity. Thus, a novel STING-activating nanoparticle will be engineered to allow for improved delivery and decreased toxicity of cGAMP. The nanoparticles, tiny bubbles composed of biocompatible polymers, are called polymerosomes and can be used to encapsulate cGAMP reducing its exposure to the body. This will create a safer formulation of cGAMP, which can be tested further in animal tumour models. It is expected that this formulation will activate the STING pathway, which will result in an immune response that will destroy tumour cells and create lasting T cell memory in the case of relapse.
Competitiondate
201711
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Wehbe, Mohamed
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~